Please use this identifier to cite or link to this item:
Title: American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and European Society for Blood and Marrow Transplantation Clinical Practice Recommendations for Transplantation and Cellular Therapies in Mantle Cell Lymphoma
Author: Munshi, Pashna N.
Hamadani, Mehdi
Kumar, Ambuj
Dreger, Peter
Friedberg, Jonathan W.
Dreyling, Martin
Kahl, Brad
Jerkeman, Mats
Kharfan-Dabaja, Mohamed A.
Locke, Frederick L.
Shadman, Mazyar
Hill, Brian T.
Ahmed, Sairah
Herrera, Alex F.
Sauter, Craig S.
Bachanova, Veronika
Ghosh, Nilanjan
Lunning, Matthew
Kenkre, Vaishalee P.
Aljurf, Mahmoud
Wang, Michael
Maddocks, Kami J.
Leonard, John P.
Kamdar, Manali
Phillips, Tycel
Cashen, Amanda F.
Inwards, David J.
Sureda, Anna
Cohen, Jonathon B.
Smith, Sonali M.
Carlo-Stella, Carmelo
Savani, Bipin N.
Robinson, Stephen P.
Fenske, Timothy S.
Keywords: Cèl·lules B
Malalties del sistema limfàtic
Trasplantament d'òrgans
B cells
Lymphatic diseases
Transplantation of organs
Issue Date: 1-Sep-2021
Publisher: Elsevier
Abstract: Autologous (auto-) and allogeneic (allo-) hematopoietic cell transplantation (HCT) are accepted treatment modalities in contemporary treatment algorithms for mantle cell lymphoma (MCL). Chimeric antigen receptor (CAR) T cell therapy recently received approval for MCL; however, its exact place and sequence in relation to HCT remain unclear. The American Society of Transplantation and Cellular Therapy, Center of International Blood and Marrow Transplant Research, and the European Society for Blood and Marrow Transplantation jointly convened an expert panel to formulate consensus recommendations for role, timing, and sequencing of auto-HCT, allo-HCT, and CAR T cell therapy for patients with newly diagnosed and relapsed/refractory (R/R) MCL. The RAND-modified Delphi method was used to generate consensus statements. Seventeen consensus statements were generated, with a few key statements as follows: in the first line setting, auto-HCT consolidation represents standard of care in eligible patients, whereas there is no clear role of allo-HCT or CAR T cell therapy outside of clinical trials. In the R/R setting, the preferential option is CAR T cell therapy, especially in patients with MCL failing or intolerant to at least one Bruton's tyrosine kinase inhibitor, while allo-HCT is recommended if CAR T cell therapy fails or is infeasible. Several recommendations were based on expert opinion, where the panel developed consensus statements for important real-world clinical scenarios to guide clinical practice. In the absence of contemporary evidence-based data, the panel found RAND-modified Delphi methodology effective in providing a formal framework for developing consensus recommendations for the timing and sequence of cellular therapies for MCL.
Note: Reproducció del document publicat a:
It is part of: Transplantation and Cellular Therapy, 2021, vol. 27, num. 9, p. 720-728
Related resource:
ISSN: 2666-6367
Appears in Collections:Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
1-s2.0-S2666636721007442-main.pdf394.7 kBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons